New Drug Improves Neurological Symptoms in Ataxia-Telangiectasia

IntraBio Inc. has announced the publication of pivotal Phase III clinical trial results for levacetylleucine in The Lancet Neurology. The study successfully met its primary endpoint, showing a statistically significant improvement in neurological symptoms and function for patients with Ataxia-Telangiectasia compared to placebo. This represents a significant positive development for individuals affected by this rare genetic disorder.